

Beruflicher Werdegang:

Herr Prof. Priv.-Doz. Dr. med. Florian Eckel hat an der Universität Regensburg und an der Technischen Universität München studiert. Nach dem Staatsexamen 1996 begann er seine klinische Ausbildung zunächst am Klinikum Kaufbeuren, wechselte aber schon bald an das Klinikum rechts der Isar der TU München.

1997 folgten die Promotion („Lebensqualität nach Gastrektomie wegen Magencarcinoms – subtotale versus totale Gastrektomie“) und 1998 die Approbation.

Seine Facharztausbildung absolvierte er an der II. Medizinischen Klinik, Klinikum rechts der Isar bei Prof. Classen. Nach dem Facharzt für Innere Medizin 2005 folgten 2006 die Schwerpunktbezeichnungen Hämatologie und Internistische Onkologie und 2007 die Schwerpunktbezeichnung Gastroenterologie.

Nach Ernennung zum Funktionsoberarzt der Intensivstation der II. Medizinischen Klinik 2007 wurde Prof. Priv.-Doz. Dr. Eckel 2008 zum Oberarzt der Klinik ernannt. Er war unter anderem tätig in der Endoskopie und Leberambulanz (Hepatology).

Im selben Jahr folgte die Habilitation („Palliative Chemotherapie fortgeschrittener hepatobiliärer und pankreatischer Karzinome“) und die Ernennung zum Privatdozenten. Die Zusatzbezeichnung Spezielle Internistische Intensivmedizin absolvierte er 2009.

Seit 2009 ist Prof. Priv.-Doz. Dr. Eckel Chefarzt der Abteilung für Innere Medizin der RoMed Klinik Bad Aibling.

Im November 2020 wurde er durch die Technische Universität München zum außerplanmäßigen Professor bestellt.

Literaturverzeichnis:

1. Eckel F, Kuesters F, Drossel B, Konert M, Mattes H, Schopf S. Variplex (TM) test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction. Eur J Clin Microbiol Infect Dis. 2020 Dec;39(12):2373–7.
2. Abdelhafez M, Phillip V, Hapfelmeier A, Sturm V, Elnegouly M, Dollhopf M, et al. Comparison of cap-assisted endoscopy vs. side-viewing endoscopy for examination of the major duodenal papilla: a randomized, controlled, noninferiority crossover study. ENDOSCOPY. 2019 May;51(5):419–26.
3. Huber W, Mayr U, Umgelter A, Franzen M, Reindl W, Schmid RM, et al. Mandatory criteria for the application of variability-based parameters of fluid responsiveness: a prospective study in different groups of ICU patients. J ZHEJIANG Univ-Sci B. 2018 Jul;19(7):515–24.

4. Eckel F, Schmid RM. Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. CHEMOTHERAPY. 2014;60(1):13–23.
5. Buck AK, Herrmann K, Eckel F, Beer AJ. Pancreatic and Hepatobiliary Cancers. In: Juweid, ME and Hoekstra, OS, editor. POSITRON EMISSION TOMOGRAPHY. 2011. p. 243–64. (Methods in Molecular Biology; vol. 727).
6. Eckel F, Brunner T, Jelic S, Grp EGW. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22(6):vi40–4.
7. Eckel F, Brunner T, Jelic S, Grp EGW. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21(5):v65–9.
8. Bajbouj M, Becker V, Eckel F, Miehke S, Pech O, Prinz C, et al. Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations. GASTROENTEROLOGY. 2009 Aug;137(2):440–4.
9. Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, et al. Gastrointestinal Oncology - Therapy Update 2008/2009. Z Gastroenterol. 2009 Mar;47(3):296–306.
10. Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause B-J, et al. Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker F-18-Fluorothymidine. J Nucl Med. 2009 Sep;50(9):1441–7.
11. Eckel F, Jelic S, Grp EGW. Biliary cancer: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20:46–8.
12. Hamacher R, Diersch S, Scheibel M, Eckel F, Mayr M, Rad R, et al. Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer. CYTOKINE. 2009 May;46(2):182–6.
13. Herrmann K, Eckel F, Hillerer C, Krause B-J, Schuster T, Langer R, et al. Imaging of proliferation in hepatocellular carcinoma (HCC) with the in-vivo marker FLT. J Nucl Med. 2009 May;50(2).
14. Herrmann K, Erkan M, Eckel F, Krause B-J, Wester H-J, Kleeff J, et al. Evaluation of 3-deoxy-3-18fluorothymidine PET (FLT-PET) for the detection of pancreatic cancer - Comparison to FDG-PET/CT. J Nucl Med. 2009 May;50(2).
15. Herrmann K, Eckel F, Schmidt S, Hillerer C, Krause B, Schuster T, et al. Evaluation of the in-vivo proliferation marker FLT for imaging of hepatocellular carcinoma. Eur J Nucl Med Mol IMAGING. 2008 Oct;35(2):S270.
16. Herrmann K, Eckel F, Schmidt S, Scheidhauer K, Krause BJ, Kleeff J, et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med. 2008 Sep;49(9):1437–44.
17. Huber W, Umgelter A, Reindl W, Franzen M, Schmidt C, von Delius S, et al. Volume assessment in patients with necrotizing pancreatitis: A comparison of

intrathoracic blood volume index, central venous pressure, and hematocrit, and their correlation to cardiac index and extravascular lung water index. *Crit CARE Med.* 2008 Aug;36(8):2348–54.

18. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. *Br J CANCER.* 2007 Mar 26;96(6):896–902.
19. Eckel F, Schmid RM. Emerging drugs for biliary cancer. *EXPERT Opin Emerg DRUGS.* 2007 Nov;12(4):571–89.
20. Schulte-Frohlinde E, Wagenpfeil S, Willis J, Lersch C, Eckel F, Schmid R, et al. Role of meal carbohydrate content for the imbalance of plasma amino acids in patients with liver cirrhosis. *J Gastroenterol Hepatol.* 2007 Aug;22(8):1241–8.
21. von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. *Thromb Haemost.* 2007 Aug;98(2):434–9.
22. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. *Invest New Drugs.* 2007 Apr;25(2):173–80.
23. von Delius S, Lersch C, Mayr M, Stock K, Schulte-Frohlinde E, Schmid RM, et al. Capecitabine for treatment of advanced hepatocellular carcinoma. *Hepatogastroenterology.* 2007 Dec;54(80):2310–4.
24. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. *EXPERT Opin Investig DRUGS.* 2006 Nov;15(11):1395–410.
25. Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acetylcysteine, theophylline, or both? A Randomized study. *RADIOLOGY.* 2006 Jun;239(3):793–804.
26. von Delius S, Lersch C, Schulte-Frohlinde E, Fend F, Dobritz M, Schmid R, et al. Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver. *Z Gastroenterol.* 2006 Jan;44(1):39–42.
27. Eckel F, von Delius S, Dobritz M, Fend F, Hosius C, Schleyer E, et al. Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma (HCC). *J Clin Oncol.* 2005 Jun 1;23(16, 1, S):341S.
28. Eckel F, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. *ONCOLOGY.* 2005;69(5):363–71.
29. Schneider G, Siveke J, Eckel F, Schmid R. Pancreatic cancer: Basic and clinical aspects. *GASTROENTEROLOGY.* 2005 May;128(6, SI):1606–25.

30. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid R, Eckel F. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. *BMC CANCER*. 2005 Jun 12;5.
31. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - A critical evaluation. *Hepatogastroenterology*. 2004 Aug;51(58):1099–103.
32. Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. *Cancer Invest*. 2003;21(5):690–4.
33. Eckel F, Huber W, Heidecke C, Moessmer G, Berger H, Holper K, et al. Fulminate intracardiac thrombosis associated with Budd-Chiari-syndrome and inferior vena cava thrombosis. *VASA-J Vasc Dis*. 2002 Feb;31(1):62–5.
34. Eckel F, Huber W, Weiss W, Lersch C. Recurrent pseudomembranous colitis as a cause of recurrent severe sepsis. *Z Gastroenterol*. 2002 Apr;40(4):255–8.
35. Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E. Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: A pilot study. *Cancer Invest*. 2002;20(2):180–5.
36. Eckel F, Lersch C, Lippl F, Schulte-Frohlinde E, Schusdzarra V, Helmberger H, et al. Monitoring of tumour glucose metabolism by PET in a phase I study evaluating hormonal therapy in advanced pancreatic cancer. *Scand J Gastroenterol*. 2002 Aug;37(8):972–7.
37. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine: A pilot study. *Dtsch Med Wochenschr*. 2002 Jan 18;127(3):78–82.
38. Huber W, Eckel F, Saur D, Sennefelder A, Hennico R, Schenk C, et al. Prophylaxis of contrast-induced nephropathy: acetylcysteine, theophylline or both - a randomized study. *INTENSIVE CARE Med*. 2002 Sep;28(1):S139.
39. Huber W, Hennig M, Eckel F, Classen M. Kidney failure related to contrast media is not manageable with hemodialysis. *Dtsch Med Wochenschr*. 2002 Jan 4;127(1–2):45–6.
40. Huber W, Jeschke B, Kreyman B, Hennig M, Page M, Salmhofer H, et al. Haemodialysis for the prevention of contrast-induced nephropathy - Outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. *Invest Radiol*. 2002 Sep;37(9):471–81.
41. Huber W, Gorge L, Eckel F, Lippl F, Saur D, Kreyman B, et al. Fulminant hepatic failure: Aetiology, diagnosis, therapy and outcome of 30 patients. *INTENSIVE CARE Med*. 2001 Sep;27(2):S207.
42. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na⁺ channel kinetics on rat sensory neurons. *Eur J Pharmacol*. 2000 Oct 6;406(1):25–32.

43. Born P, Lippl F, Ulm K, Gerein P, Lersch C, Eckel F, et al. Reduced levels of coagulation factor XIII in patients with advanced tumor disease. *Hepatogastroenterology*. 2000 Feb;47(31):194–8.
44. Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E. Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. *Ann Oncol*. 2000 Jun;11(6):762–3.
45. Eckel F, Lersch C, Erdmann J, Schmidt B, Schulte-Frohlinde E. A 42-year-old man with hemolytic-uremic syndrome associated with gemcitabine therapy for adenocarcinoma of the liver. *Z Gastroenterol*. 2000 Jul;38(7):593–6.
46. Eckel F, Lersch C, Huber W, Weiss W, Berger H, Schulte-Frohlinde E. Multimicrobial sepsis including *Clostridium perfringens* after chemoembolization of a single liver metastasis from common bile duct cancer. *DIGESTION*. 2000;62(2–3):208–12.
47. Eckel F, Lersch C, Lippl F, Assmann G, Schulte-Frohlinde E. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. *J Exp Clin CANCER Res*. 2000 Sep;19(3):295–300.
48. Lersch C, Eckel F, Assmann G, Adelsberger H, Quasthoff S, Schulte-Frohlinde E, et al. Prevention of peripheral sensory neuropathy (PSN) by carbamazepine in patients with advanced colorectal cancers (ACRC) treated with oxaliplatin. A pilot study. *GASTROENTEROLOGY*. 2000 Apr;118(4, 1, 2):A522.
49. Weigert N, Eckel F, Born P, Erhardt W, Henke J, Werner M, et al. Endohyperthermia - Experimental evaluation of a new therapeutic approach for treatment of biliary carcinoma. *ENDOSCOPY*. 2000 Apr;32(4):306–10.
50. Lersch C, Eckel F, Sader R, Paschalidis M, Zeilhofer F, Schulte-Frohlinde E, et al. Initial experience with Healthport miniMax (R) and other peripheral arm ports in patients with advanced gastrointestinal malignancy. *ONCOLOGY*. 1999;57(4):269–75.
51. Weigert N, Eckel F, Roesch T, Erhardt W, Werner M, Classen M. Endohyperthermia (EHT) - Experimental evaluation of a new form of endobiliary tumor treatment. *Gastrointest Endosc*. 1999 Apr;49(4, 2):AB133.
52. Eckel F, Ugi I, Schmidt T, Lersch C. A 44-year-old man with carcinoma of the cardia and paraneoplastic orbital involvement. *Dtsch Med Wochenschr*. 1998 Sep 18;123(38):1103–6.
53. Kauer W, Roder J, Stein H, Eckel F, Siewert J. Quality-of-life assessment following pancreatoduodenectomy with and without preservation of the pylorus. *GASTROENTEROLOGY*. 1996 Apr;110(4, S):A1396.
54. Roder J, Stein H, Eckel F, Herschbach P, Henrich G, Bottcher K, et al. Quality of life after subtotal and total gastrectomy for gastric carcinoma. *Dtsch Med Wochenschr*. 1996 Apr 26;121(17):543–9.
- 55.